Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Industrifonden on the investment in Aprea AB
Mandate

Vinge advises Industrifonden on the investment in Aprea AB

November 07, 2007

Vinge advises Industrifonden on its investment in Aprea AB, a pharmaceutical company that develops and carries out research on a new drug against cancer. Aprea will raise MSEK 50 through this share issue of which Industrifonden contributes with MSEK 25 and will thereby become a new owner in the company.

Industrifonden is represented by partner Johan Winnerblad with assistance from Johan Larsson.

Related

Vinge advises Diamyd Medical in connection with directed issuances of shares and warrants of up to SEK 1,166 million

 Vinge advises Diamyd Medical Aktiebolag (“Diamyd Medical”), listed on Nasdaq First North Growth Market, in connection with directed issuances of shares and warrants whereby Diamyd Medical receives gross proceeds of approximately SEK 1,166 million, if all warrants are exercised.
March 25, 2026

Vinge has advised Resurs in connection with its strategic partnership with Kustom

 Vinge has advised Resurs in connection with its strategic partnership with Kustom (formerly Klarna Checkout), a fast-growing player in the digital commerce sector. The partnership enables Resurs to accelerate its strategic development by offering a check-out solution to its merchants, built on Kustom’s market-leading infrastructure.
March 25, 2026

Vinge has advised Morrow Bank AB (publ) in conjunction with the acquisition of MedMera Bank AB

 Vinge has advised Morrow Bank AB (publ) in conjunction with the acquisition of all shares in MedMera Bank AB from Kooperativa Förbundet for a total consideration of SEK 1,960 million. The transaction positions Morrow Bank as a leading Nordic platform in consumer finance with combined gross loans of SEK 28.2 billion.
March 24, 2026